[CAL-101,a novel agent of targeted therapy in hematological malignancies]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):530-3. doi: 10.7534/j.issn.1009-2137.2014.02.049.
[Article in Chinese]

Abstract

CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migration of tumor cells by directly inducing apoptosis and inhibiting micro-environmental interactions. It has been determined that the P110δ isoforms of PI3K expressed primarily in cells of hematopoietic lineage, such as B and T cells. This review focuses on the target, mechanism of action, the use and prospect of CAL-101 in tumors of blood and lymph systems.

Publication types

  • Review

MeSH terms

  • Animals
  • Hematologic Neoplasms / drug therapy*
  • Humans
  • Phosphoinositide-3 Kinase Inhibitors
  • Purines / pharmacology
  • Purines / therapeutic use*
  • Quinazolinones / pharmacology
  • Quinazolinones / therapeutic use*
  • Signal Transduction / drug effects

Substances

  • Phosphoinositide-3 Kinase Inhibitors
  • Purines
  • Quinazolinones
  • idelalisib